Combination therapy with candesartan and lisinopril was more effective than monotherapy in type 2 diabetes and hypertension


**Question**
What are the effects of candesartan or lisinopril, or both, on blood pressure and the urinary albumin excretion rate in patients with hypertension, microalbuminuria, and type 2 diabetes mellitus?

**Design**
Randomized (unclear allocation concealment*), double-blind (investigators and patients),* controlled trial with 24-week follow-up.

**Setting**
37 centers in tertiary hospitals and primary care sites (12 in Australia, 9 in Denmark, 4 in Finland, and 12 in Israel).

**Patients**
199 patients between 30 and 75 years of age with type 2 diabetes, microalbuminuria (urinary albumin-to-creatinine ratio between 2.5 and 25 mg/mmol), and diastolic blood pressure (BP) between 90 and 110 mm Hg while receiving placebo. Exclusion criteria included body mass index ≥ 40 kg/m², systolic BP > 200 mm Hg, nondiabetic cause of secondary hypertension, cardiovascular event in the previous 6 months, elevated serum creatinine and potassium levels, and hemoglobin A₁c level > 10%. 197 patients (99%) (mean age 60 y, 65% men) had complete follow-up.

**Intervention**
After a 4-week placebo run-in period, patients were allocated to 1 of 4 groups: candesartan for 24 weeks (n = 66), lisinopril for 24 weeks (n = 64), candesartan for 12 weeks with the addition of lisinopril for a subsequent 12 weeks (n = 34), or lisinopril for 12 weeks with the addition of candesartan for a subsequent 12 weeks (n = 35). Patients in the latter 2 groups receiving combination regimens were combined in the 24-week analysis. Doses used were candesartan, 16 mg once daily, and lisinopril, 20 mg once daily.

**Main outcome measures**
BP, urinary albumin-to-creatinine ratio, hemoglobin A₁c level, and adverse effects.

**Main results**
Analysis was by intention to treat. All treatments were effective in reducing BP and the urinary albumin-to-creatinine ratio. At 24 weeks, the mean reduction from baseline in diastolic BP was greater with combination treatment (16.3 mm Hg) than with candesartan alone (10.4 mm Hg, P = 0.003) or lisinopril alone (10.7 mm Hg, P = 0.005). Similarly, the mean reduction from baseline in systolic BP was greater with combination treatment (25.3 mm Hg) than with candesartan alone (14.1 mm Hg, P = 0.002) or lisinopril alone (16.7 mm Hg, P = 0.02). Combination treatment was associated with a greater mean reduction from baseline in urinary albumin-to-creatinine ratio than was candesartan alone (50% vs 24%, P = 0.04) but not lisinopril alone (50% vs 39%, P > 0.20). Groups did not differ for changes in mean hemoglobin A₁c levels. In general, all treatments were well tolerated.

**Conclusions**
Candesartan and lisinopril were effective monotherapies for reducing blood pressure and microalbuminuria; however, their combined use was well tolerated and more effective for reducing blood pressure in patients with type 2 diabetes, hypertension, and microalbuminuria.


For correspondence: Dr. C.E. Mogensen, Kommunehospitalet, University Hospital, DK-8000 Aarhus C, Denmark. FAX 45-89492010.

*See Glossary.

**Commentary**
Type 2 diabetes, hypertension, microalbuminuria, and cardiovascular disease are components of the insulin resistance syndrome. In many studies of patients with diabetes and microalbuminuria, angiotensin-converting enzyme (ACE) inhibitors have been more effective than have other agents in the short-term reduction of microalbuminuria. Angiotensin-II receptor antagonists have many properties that are similar to ACE inhibitors. However, they do not inhibit the breakdown of bradykinin, which causes the cough that is the most common side effect of ACE-inhibitor therapy.

This study by Mogensen and colleagues compared the effects of an angiotensin-II receptor antagonist, candesartan, and an ACE inhibitor, lisinopril, on BP and microalbuminuria in patients with type 2 diabetes. Both drugs decreased BP and microalbuminuria, and the effect was even greater when the 2 drugs were combined. What remains unclear is whether similar benefits would have been obtained by increasing the dose of each agent; the benefit for microalbuminuria was because the renin-angiotensin system was blocked more completely with both agents or because BP was reduced more effectively; or similar benefits might have been obtained if other agents had been added in combination.

The Hypertension in Diabetes Study (HDS) (1) and Hypertension Optimal Treatment (HOT) trial (2) showed that aggressive treatment of hypertension in people with type 2 diabetes was associated with a reduction in cardiovascular outcomes. The 2 studies also showed that multiple hypotensive agents of different classes were needed to reach the target BP. Subsequently, the Heart Outcomes Prevention Evaluation (HOPE) study (3) showed that the ACE inhibitor, ramipril, had cardiovascular benefits beyond the reduction in BP. As a result, ACE inhibitors have become the drug of first choice for treating hypertension in persons with type 2 diabetes. The current study suggests that angiotensin-II receptor antagonists should be considered if target BP is not reached. Trials are ongoing to determine whether angiotensin-II receptor antagonists have benefits similar to those seen in the HOPE and other trials.

Miles Fisher, MD
Glasgow Royal Infirmary
Glasgow, Scotland, UK

**References**